STAT May 28, 2024
Andrew Joseph

An experimental drug from Insmed Incorporated successfully reduced lung problems among patients with an airway disease in a closely watched Phase 3 trial, sending the company’s share price soaring early Tuesday.

The drug, brensocatib, reduced so-called pulmonary exacerbations by roughly 20% versus placebo in patients with bronchiectasis, hitting the trial’s...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Clinical Trials, Pharma, Pharma / Biotech, Trends
Kroger partners with Express Scripts to expand pharmacy services
Denali’s Data in Rare Enzyme Deficiency Keep It on Pace to Seek Speedy FDA Approval
Vertex challenger Sionna prices $191M IPO
Some of the Biggest Healthcare Stories from 2024 Involved Pharmacy. What’s Next in 2025?
Insights from JP Morgan 2025: Key trends shaping the pharma industry

Share This Article